Breast Cancer
A large international breast cancer research team (published in "Nature"), made the eye-opening discovery of how receptors that mediate activity of the female sex hormones (estrogen and progesteronE) interact with DNA to control the growth of hormone-receptor positive breast cancers. (Mohammed et al, 2015).
The American Cancer Society estimates that 2 out of 3 breast cancer cases are hormone-receptor positive.
• Estrogen activates estrogen receptors, which are agents that turn on cancer-promoting genes in breast cancer.
• PROGESTERONE activates progesterone receptors, which bind to and 'reprogram' estrogen receptors, transforming them into agents that turn on genes to slow down or reverse the cancer cell growth.
The researchers emphasize that their conclusions ONLY apply to natural, BIOIDENTICAL progesterone.
The Woman's Health Initiative (WHI) study demonstrated that a combination of Premarin (conjugated equine estrogens (CEEs, primary ingredients: sodium estrone sulfateand sodium equilin sulfate, which convert to ESTRADIOL, then ESTRONE) and Provera (the progestin Medroxyprogesterone acetate (MPA), a synthetic progesteronE) produces a 26% increase in invasive breast cancer. (Rossouw et al, 2002)
The risk of breast cancer was significantly greater with HRT utilizing CEE's with Provera™) (containing the progestin MPA) than with HRT containing micronized progesterone. (Fournier et al, 2005) or when utilizing a non-CEE estrogen combined with a progestin other than MPA (de Lignières et al)
Synthetic Sex Steroids - "Frankinstein Forms
Since estrogen dominance over progesterone is a common problem today BIOIDENTICAL PROGESTERONE supplementation in hormone-sensitive breast cancers could indeed increase survival rates.
Estrogen dominance treatment 1-2-3
How to supplement PROGESTERONE
Women with
estrogen dominance, where progesterone levels are low relative to
estrogen levels, are more likely
to get breast cancer and have poorer treatment outcomes. Drs Zava and
Lee and Virginia Hopkins, coauthors of
What Your Doctor May Not Tell You About™ Breast Cancer, concluded that
estrogen dominance causes
estrogen receptors to
activate genes such as Bcl-2 that are known to promote the rapid growth of
cancer cells.
When progesterone is raised to healthy levels relative to estrogen, it turns on genes that can prevent breast cancer from occurring and reduce the size of existing tumors. Dr. Lee and Dr. Zava cited research showing that progesterone receptors activate genes such as p53 that promote apoptosis (body's method of destroying cancer cells before they develop into tumors).
Mohammed, Hisham, et al (2015) Progesterone receptor modulates ER-a action in breast cancer. Nature ; 523; 313-317. Link.
Perks, Bea (17 Jul 2015) Progesterone receptor could slow breast cancer growth. Pharmaceutical Journal. LInk.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002 Jul 17) Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 288(3):321-33 PubMed
de Lignières B, de Vathaire F, Fournier S, Urbinelli R, Allaert F, Le MG, Kuttenn F. (2002 Dec) Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric. 5(4):332-40. Researchgate
Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. (2005 Apr 10) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 114(3):448-54. PubMed
